

RECEIVED
Atty Dkt: APF 18.20
03 JUL -8 PM 1:15 PATENT

Certificate of Deposit:

Date of Deposit: July 8, 2003

I hereby certify that this paper and all noted attachments are being hand-deposited with the United States Patent and Trademark Office, Attn: Mail Stop RCE, on the date indicated above.

Jennifer Lohse
Typed or Printed Name of Person Depositing Paper

Jennifer Lohse
Signature of Person Depositing Paper

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Haynes et al.

Serial No.: 09/433,777

Art Unit: 1632

Filing Date: 3 November 1999

Examiner: A.M.S. Wehbe

Title: ADJUVANTED GENETIC VACCINES

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)**

Commissioner for Patents
Washington, D.C. 20231

Sir:

The information listed below may be material to the examination of the above-identified application. Copies of the information and completed PTO-1449 forms are

submitted herewith. The Examiner is respectfully requested to make this information of official record in the application. The information includes:

United States Patent No. 5,630,796 issued May 20, 1997 to Bellhouse et al.;

United States Patent No. 4,945,050 issued July 30, 1990 to Sanford et al.;

United States Patent No. 5,100,792 issued March 31, 1992 to Sanford et al.;

United States Patent No. 5,120,657 issued June 9, 1992 to McCabe et al.;

United States Patent No. 5,149,655 issued September 22, 1992 to McCabe et al.;

United States Patent No. 5,204,253 issued April 20, 1993 to Sanford et al.;

United States Patent No. 5,584,807 issued December 17, 1996 to McCabe;

United States Patent No. 5,589,466 issued December 31, 1996 to Felgner et al.;

United States Patent No. 5,630,496 issued May 20, 1997 to Bellhouse et al.;

United States Patent No. 5,738,852 issued April 14, 1998 to Robinson et al.;

United States Patent No. 5,865,796 issued February 2, 1999 to McCabe;

United States Patent No. 6,168,587 issued January 2, 2001 to Bellhouse et al.;

United States Patent No. 6,194,389 issued February 27, 2001 to Johnston et al.;

International Publication No. WO 94/24263, published October 27, 1994;

International Publication No. WO 95/19799, published July 27, 1995;

International Publication No. WO 96/04947, published February 22, 1996;

International Publication No. WO 96/12513, published May 02, 1996;

International Publication No. WO 96/14855, published May 23, 1996;

International Publication No. WO 96/20022, published July 04, 1996;

International Publication No. WO 97/32987, published September 12, 1997;


International Publication No. WO 97/48485, published December 24, 1997;

International Publication No. WO 98/10750, published March 19, 1998;
International Publication No. WO 98/46263, published October 22, 1998;
International Publication No. WO 99/27961, published June 10, 1999;
International Publication No. WO 00/12121, published March 09, 2000;
International Publication No. WO 00/13704, published March 16, 2000;
Haynes J R, "Genetic Vaccines," *Infectious Disease Clinics Of North America*.
13(1):11-26 (1999);
Sasaki et al., "The Search for a Potent DNA Vaccine against AIDS: The
Enhancement of Immunogenicity by Chemical & Genetic Adjuvants", *Anticancer research*
18:3907-3916 (1998);
Sasaki et al., "Monophosphoryl Lipid A Enhances Both Humoral & Cell-Mediated
Immune Responses to DNA Vaccination against Human Immunodeficiency Virus Type 1",
Infection & immunity. 65(9):3520-3528 (1997);
Lodmell et al., "DNA Vaccination of mice against rabies virus: effects of the route of
vaccination and the adjuvant monophosphoryl lipid A (MPL)" *Vaccine*. 18:1059-1066
(2000); and
Pow & Crook, "Extremely high titre polyclonal antisera against small
neurotransmitter molecules: rapid production, Characterisation and use in light-and
electron-microscopic immunocytochemistry", *J. of Neuroscience Methods*. 48:51-63 (1993).

This Information Disclosure Statement under 37 CFR § 1.97(b) is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the

information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Respectfully submitted,

By: 
Thomas P. McCracken
Registration No. 38,548

POWDERJECT PHARMACEUTICALS PLC
Florey House, The Oxford Science Park
Oxford OX4 4GA
Telephone: +44 1865 332 600
Fax: +44 1865 332 601